Streetwise Reports' Article Archives — October 2018 back to current month (23)

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential' (10/31/2018)

A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications.

more>

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment (10/31/2018)

With this achievement, the firm expands its potential partnering opportunities.

more>

Three Small-Caps on This Fund Manager's List (10/30/2018)

Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following.

more>

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed (10/29/2018)

Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed.

more>

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers (10/27/2018)

Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company.

more>

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs (10/27/2018)

Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer.

more>

Catasys…Future's So Bright (10/27/2018)

Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions.

more>

Biotech to Expand Precision Medicine Services via New Partnership (10/24/2018)

A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology.

more>

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View (10/24/2018)

Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp.

more>

Animal Health Product Developer to Expand Sales Footprint (10/20/2018)

This Canadian company makes progress with its commercial uptake efforts.

more>

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant (10/20/2018)

An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology.

more>

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner (10/17/2018)

Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space.

more>

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder (10/17/2018)

This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication.

more>

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership (10/13/2018)

This "patient-care solution" is designed to help retailers make product recommendations.

more>

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease (10/11/2018)

Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates.

more>

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential' (10/10/2018)

A LifeSci Capital report presented a handful of key points about the firm.

more>

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential (10/10/2018)

An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential.

more>

Texas Heart Takes to the CoreoGraft (10/10/2018)

Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery.

more>

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements (10/09/2018)

This Utah-based company rolled out an online campaign that highlights its strategic repositioning.

more>

DURECT Receives Return on Schizophrenia Drug Approval (10/03/2018)

A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm.

more>

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters (10/03/2018)

An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it.

more>

Surgical Robotics Developer Demonstrates Technology at Medical Conference (10/03/2018)

A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system.

more>

Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed (10/01/2018)

As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative.

more>

More Archives

2019Aug Jul Jun May Apr Mar Feb Jan

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes

"DRRX earned a $10M milestone payment from Gilead."
– Ed Arce, H.C. Wainwright & Co.